Please login to the form below

Not currently logged in
Email:
Password:

Hodgkin's lymphoma

This page shows the latest Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti. Adds to firm's growing oncology franchise. ... Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast

Latest news

More from news
Approximately 19 fully matching, plus 137 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.

  • Interview: Kay Drake and Naoki Okamura, Astellas Interview: Kay Drake and Naoki Okamura, Astellas

    The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    The significance of this lays in the evolving nature of Takeda's portfolio. “ ... Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Australian Flu and the dilemma of naming diseases

    Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century Hodgkin’ ... s Lymphoma and Parkinsons.

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics